Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00989872 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers
A Phase 1 study, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT00989872 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 67 participants.
The verdict
NCT00989872, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This was a randomized, double-blind, placebo-controlled, ascending single dose safety, tolerability, and pharmacokinetic study of orally administered EDP-322. This study was conducted at a single site. EDP-322 has a benefit to risk profile that supports testing in target patient populations.
Interventions
- DRUG EDP-322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00989872
The ClinicalTrials.gov registry entry for NCT00989872 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EDP-322 is the first listed.
NCT00989872 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00989872 about?
NCT00989872 is a clinical study titled "Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers". This was a randomized, double-blind, placebo-controlled, ascending single dose safety, tolerability, and pharmacokinetic study of orally administered EDP-322. This study was conducted at a single site. EDP-322 has a benefit to risk profile that supports testing in target patient populations.
What is the current status of trial NCT00989872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants.
What interventions are being tested in trial NCT00989872?
The interventions under investigation include: EDP-322 (DRUG).
Who is sponsoring clinical trial NCT00989872?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.